The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives

Bibliography

• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23(5):1011-27
   PubMed Web of Science ®Google Scholar
• Limaverde-Sousa G, Sternberg C, Ferreira CG. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev 2014;40(4):548-57
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-24
   PubMed Web of Science ®Google Scholar
• Li B, Fuh G, Meng G, et al. Receptor-selective variants of human vascular endothelial growth factor. Generation and characterization. J Biol Chem 2000;275(38):29823-8
   PubMed Web of Science ®Google Scholar
• Lu D, Jimenez X, Zhang H, et al. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer 2002;97(3):393-9
   PubMed Web of Science ®Google Scholar
• Gille H, Kowalski J, Li B, et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 2001;276(5):3222-30
   PubMed Web of Science ®Google Scholar
• Poole RM, Vaidya A. Ramucirumab: first global approval. Drugs 2014;74(9):1047-58
   PubMed Web of Science ®Google Scholar
• Hyder SM, Stancel GM. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol 1999;13(6):806-11
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1(1):27-31
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407(6801):249-57
   PubMed Web of Science ®Google Scholar
• Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175(3):409-16
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3(6):401-10
   PubMed Web of Science ®Google Scholar
• Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2(11):826-35
   PubMed Web of Science ®Google Scholar
• Mentzer SJ, Konerding MA. Intussusceptive angiogenesis: expansion and remodeling of microvascular networks. Angiogenesis 2014;17(3):499-509
   PubMed Web of Science ®Google Scholar
• Ribatti D, Crivellato E. “Sprouting angiogenesis”, a reappraisal. Dev Biol 2012;372(2):157-65
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25(4):581-611
   PubMed Web of Science ®Google Scholar
• Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999;9(3):211-20
   PubMed Web of Science ®Google Scholar
• Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med 2013;273(2):114-27
   PubMed Web of Science ®Google Scholar
• Andreozzi M, Quagliata L, Gsponer JR, et al. VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities. Angiogenesis 2014;17(3):519-27
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Prud’homme GJ, Glinka Y. Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity. Oncotarget 2012;3(9):921-39
   PubMed Web of Science ®Google Scholar
• Shibuya M. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013;153(1):13-19
   PubMed Web of Science ®Google Scholar
• Chung GG, Yoon HH, Zerkowski MP, et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006;106(8):1677-84
   PubMed Web of Science ®Google Scholar
• Shen L, Zhou Q, Wang Y, et al. Antiangiogenic and antitumoral effects mediated by a vascular endothelial growth factor receptor 1 (VEGFR-1)-targeted DNAzyme. Mol Med 2013;19:377-86
   PubMed Web of Science ®Google Scholar
• Liu W, Xu J, Wang M, et al. Tumor-derived vascular endothelial growth factor (VEGF)-a facilitates tumor metastasis through the VEGF-VEGFR1 signaling pathway. Int J Oncol 2011;39(5):1213-20
   PubMed Web of Science ®Google Scholar
• Coso S, Bovay E, Petrova TV. Pressing the right buttons: signaling in lymphangiogenesis. Blood 2014;123(17):2614-24
   PubMed Web of Science ®Google Scholar
• Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994;59(4):520-9
   PubMed Web of Science ®Google Scholar
• Bruns CJ, Liu W, Davis DW, et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000;89(3):488-99
   PubMed Web of Science ®Google Scholar
• Graells J, Vinyals A, Figueras A, et al. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. J Invest Dermatol 2004;123(6):1151-61
   PubMed Web of Science ®Google Scholar
• Hsei V, Deguzman GG, Nixon A, Gaudreault J. Complexation of VEGF with bevacizumab decreases VEGF clearance in rats. Pharm Res 2002;19(11):1753-6
   PubMed Web of Science ®Google Scholar
• Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther 2009;9(2):263-71
   PubMed Web of Science ®Google Scholar
• Krupitskaya Y, Wakelee HA. Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 2009;10(6):597-605
   PubMed Web of Science ®Google Scholar
• Ciardiello F. Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs 2000;60(Suppl 1):25-32
   PubMed Web of Science ®Google Scholar
• Boro A, Arlt MJ, Lengnick H, et al. Prognostic value and in vitro biological relevance of Neuropilin 1 and Neuropilin 2 in osteosarcoma. Am J Transl Res 2015;7(3):640-53
   PubMedGoogle Scholar
• de Haas S, Delmar P, Bansal AT, et al. Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy. Angiogenesis 2014;17(4):909-20
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Yang D, et al. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One 2013;8(7):e66774
   PubMed Web of Science ®Google Scholar
• Sumbul AT, Disel U, Sezgin N, et al. Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment? Med Sci Monit 2014;20:428-33
   PubMed Web of Science ®Google Scholar
• Guo C, Buranych A, Sarkar D, et al. The role of tumor-associated macrophages in tumor vascularization. Vasc Cell 2013;5(1):20
   PubMedGoogle Scholar
• Kharaishvili G, Simkova D, Bouchalova K, et al. The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance. Cancer Cell Int 2014;14:41
   PubMed Web of Science ®Google Scholar
• Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131(3):463-75
   PubMed Web of Science ®Google Scholar
• Semenza GL. Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis. Oncogene 2013;32(35):4057-63
   PubMed Web of Science ®Google Scholar
• Conley SJ, Gheordunescu E, Kakarala P, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA 2012;109(8):2784-9
   PubMed Web of Science ®Google Scholar
• El-Kenawi AE, El-Remessy AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. Br J Pharmacol 2013;170(4):712-29
   PubMed Web of Science ®Google Scholar
• Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19(3):843-50
   PubMed Web of Science ®Google Scholar
• Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74(16):1891-925
   PubMed Web of Science ®Google Scholar
• Andre T, Chibaudel B. [Aflibercept (Zaltrap((R))) approved in metastatic colorectal cancer]. Bull Cancer 2013;100(10):1023-5
   PubMed Web of Science ®Google Scholar
• Sulkes A. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm. Isr Med Assoc J 2010;12(10):628-32
   PubMed Web of Science ®Google Scholar
• Prewett M, Huber J, Li Y, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999;59(20):5209-18
   PubMed Web of Science ®Google Scholar
• Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28(5):780-7
   PubMed Web of Science ®Google Scholar
• Chiorean EG, Hurwitz HI, Cohen RB, et al. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors. Ann Oncol 2015;26(6):1230-7
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 2011;29(30):3968-76
   PubMed Web of Science ®Google Scholar
• Wakatsuki T, Zhang W, Yang D, et al. Ethnic gene profile of genes involved in angiogenesis to predict regional bevacizumab efficacy difference in gastric cancer. ASCO Meeting Abstracts 2012;30(Suppl 15):4026
   Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014;383(9911):31-9
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15(11):1224-35
   PubMed Web of Science ®Google Scholar
• Yoon HH, Bendell JC, Braiteh FS, et al. Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. ASCO Meeting Abstracts 2014;32(Suppl 15):4004
   Google Scholar
• Zhu AX, Ryoo BY, Yen CJ, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Results from the randomized phase III REACH study. Ann Oncol 2014;25(5):1-41
   Google Scholar
• Zhu AX, Ryoo BY, Yen CJ, et al. Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Analysis of patients with elevated α-fetoprotein (AFP) from the randomized phase III REACH study. J Clin Oncol 2015;33(Suppl 3):abstract 232
   Google Scholar
• Tabernero J CAL, Obermannova R, Bodoky G, et al. RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in patients (pts) with metastatic colorectal carcinoma (CRC) progressive during or following first-line combination therapy with bevacizumab (bev), oxaliplatin (ox), and a fluoropyrimidine (fp). J Clin Oncol 2015;33(Suppl 3):abstr 512
   Google Scholar
• Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16(5):499-508
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):303-12
   PubMed Web of Science ®Google Scholar
• Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384(9944):665-73
   PubMed Web of Science ®Google Scholar
• Camidge DR, Berge EM, Doebele RC, et al. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol 2014;9(10):1532-9
   PubMed Web of Science ®Google Scholar
• Doebele RC, Spigel D, Tehfe M, et al. Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer 2015;121(6):883-92
   PubMed Web of Science ®Google Scholar
• Mackey JR, Ramos-Vazquez M, Lipatov O, et al. Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol 2015;33(2):141-8
   PubMed Web of Science ®Google Scholar
• Yardley DA, Richards PD, Reeves JA, et al. Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC). J Clin Oncol 2014;32(Suppl 15):1035
   Google Scholar
• Sledge GWJr. VEGF-targeting therapy for breast cancer. J Mammary Gland Biol Neoplasia 2005;10(4):319-23
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res 2001;61(8):3369-72
   PubMed Web of Science ®Google Scholar
• Miles DW, Dieras V, Cortes J, et al. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 2013;24(11):2773-80
   PubMed Web of Science ®Google Scholar
• Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. Lancet Oncol 2013;14(10):933-42
   PubMed Web of Science ®Google Scholar
• Slamon D, Swain S, Buyse M, et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. Cancer Res 2013;73(Suppl 24):S1-03
   Google Scholar
• Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013;14(1):29-37
   PubMed Web of Science ®Google Scholar
• Wadhwa R, Elimova E, Shiozaki H, et al. Anti-angiogenic agent ramucirumab: meaningful or marginal? Expert Rev Anticancer Ther 2014;14(4):367-79
   PubMed Web of Science ®Google Scholar
• Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68(5):1451-61
   PubMed Web of Science ®Google Scholar
• Shi M, Chen MS, Sekar K, et al. A blood-based three-gene signature for the non-invasive detection of early human hepatocellular carcinoma. Eur J Cancer 2014;50(5):928-36
   PubMed Web of Science ®Google Scholar